aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced its participation in two major investor conferences in April 2025. The company will attend the Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9) and the Piper Sandler Spring Biopharma Symposium in Boston (April 17), both featuring one-on-one investor meetings.
aTyr specializes in developing first-in-class medicines using their proprietary tRNA synthetase platform. Their lead product, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The company's innovative approach involves leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation, focusing on novel domains that regulate extracellular pathways in humans.
aTyr Pharma (Nasdaq: ATYR), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori nell'aprile 2025. L'azienda parteciperà alla Jones Healthcare and Technology Innovation Conference a Las Vegas (8-9 aprile) e al Piper Sandler Spring Biopharma Symposium a Boston (17 aprile), entrambe con incontri individuali con gli investitori.
aTyr si specializza nello sviluppo di farmaci innovativi utilizzando la propria piattaforma di sintasi tRNA. Il loro prodotto di punta, efzofitimod, è un immunomodulatore biologico di prima classe in fase di sviluppo per il trattamento delle malattie polmonari interstiziali. L'approccio innovativo dell'azienda prevede l'uso dell'intelligenza evolutiva per tradurre la biologia della sintasi tRNA in nuove terapie per la fibrosi e l'infiammazione, concentrandosi su domini innovativi che regolano le vie extracellulari negli esseri umani.
aTyr Pharma (Nasdaq: ATYR), una empresa biotecnológica en etapa clínica, ha anunciado su participación en dos importantes conferencias de inversores en abril de 2025. La empresa asistirá a la Jones Healthcare and Technology Innovation Conference en Las Vegas (8-9 de abril) y al Piper Sandler Spring Biopharma Symposium en Boston (17 de abril), ambas con reuniones individuales con inversores.
aTyr se especializa en el desarrollo de medicamentos innovadores utilizando su plataforma de sintasa de tRNA. Su producto principal, efzofitimod, es un inmunomodulador biológico de primera clase que se está desarrollando para el tratamiento de enfermedades pulmonares intersticiales. El enfoque innovador de la empresa implica aprovechar la inteligencia evolutiva para traducir la biología de la sintasa de tRNA en nuevas terapias para la fibrosis y la inflamación, centrándose en dominios novedosos que regulan las vías extracelulares en los humanos.
aTyr Pharma (Nasdaq: ATYR), 임상 단계의 생명공학 회사가 2025년 4월 두 개의 주요 투자자 회의에 참석할 것이라고 발표했습니다. 이 회사는 라스베가스에서 열리는 Jones Healthcare and Technology Innovation Conference (4월 8-9일)와 보스턴에서 열리는 Piper Sandler Spring Biopharma Symposium (4월 17일)에 참석하며, 두 회의 모두 투자자와의 일대일 미팅이 포함됩니다.
aTyr는 자사의 tRNA 합성효소 플랫폼을 사용하여 1급 의약품을 개발하는 데 전문화되어 있습니다. 그들의 주요 제품인 efzofitimod는 간질성 폐질환 치료를 위해 개발 중인 1급 생물학적 면역조절제입니다. 이 회사의 혁신적인 접근 방식은 진화적 지능을 활용하여 tRNA 합성효소 생물학을 섬유증 및 염증에 대한 새로운 치료법으로 전환하는 것을 포함하며, 인간의 세포외 경로를 조절하는 새로운 도메인에 집중하고 있습니다.
aTyr Pharma (Nasdaq: ATYR), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à deux grandes conférences d'investisseurs en avril 2025. L'entreprise assistera à la Jones Healthcare and Technology Innovation Conference à Las Vegas (8-9 avril) et au Piper Sandler Spring Biopharma Symposium à Boston (17 avril), les deux événements proposant des rencontres individuelles avec les investisseurs.
aTyr se spécialise dans le développement de médicaments de première classe en utilisant sa plateforme de synthétase tRNA. Leur produit phare, efzofitimod, est un immunomodulateur biologique de première classe en cours de développement pour le traitement des maladies pulmonaires interstitielles. L'approche innovante de l'entreprise consiste à tirer parti de l'intelligence évolutive pour traduire la biologie de la synthétase tRNA en nouvelles thérapies pour la fibrose et l'inflammation, en se concentrant sur des domaines novateurs qui régulent les voies extracellulaires chez l'homme.
aTyr Pharma (Nasdaq: ATYR), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im April 2025 angekündigt. Das Unternehmen wird an der Jones Healthcare and Technology Innovation Conference in Las Vegas (8.-9. April) und dem Piper Sandler Spring Biopharma Symposium in Boston (17. April) teilnehmen, bei beiden Veranstaltungen sind Einzelgespräche mit Investoren vorgesehen.
aTyr hat sich auf die Entwicklung von erstklassigen Medikamenten spezialisiert, die ihre proprietäre tRNA-Synthetase-Plattform nutzen. Ihr Hauptprodukt, efzofitimod, ist ein erstklassiger biologischer Immunmodulator, der zur Behandlung von interstitiellen Lungenerkrankungen entwickelt wird. Der innovative Ansatz des Unternehmens besteht darin, evolutionäre Intelligenz zu nutzen, um die Biologie der tRNA-Synthetase in neue Therapien gegen Fibrose und Entzündungen zu übersetzen und sich auf neuartige Bereiche zu konzentrieren, die extrazelluläre Wege im Menschen regulieren.
- None.
- None.
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025.
Details of the conferences appear below:
Conference: Jones Healthcare and Technology Innovation Conference
Date: April 8 – 9, 2025
Location: Las Vegas, NV
Format: 1x1 Investor Meetings
Conference: Piper Sandler Spring Biopharma Symposium
Date: April 17, 2025
Location: Boston, MA
Format: 1x1 Investor Meetings
For more information on how to register, please contact your Jones or Piper Sandler representative.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
What investor conferences will aTyr Pharma (ATYR) attend in April 2025?
What is aTyr Pharma's (ATYR) lead therapeutic candidate?
What is the focus of aTyr Pharma's (ATYR) discovery platform?
What medical conditions does aTyr Pharma (ATYR) target with their therapies?
